HK1173219A1 - Screening method utilizing thalidomide-targeting factor - Google Patents

Screening method utilizing thalidomide-targeting factor

Info

Publication number
HK1173219A1
HK1173219A1 HK13100395.6A HK13100395A HK1173219A1 HK 1173219 A1 HK1173219 A1 HK 1173219A1 HK 13100395 A HK13100395 A HK 13100395A HK 1173219 A1 HK1173219 A1 HK 1173219A1
Authority
HK
Hong Kong
Prior art keywords
thalidomide
screening method
method utilizing
targeting factor
targeting
Prior art date
Application number
HK13100395.6A
Other languages
English (en)
Chinese (zh)
Inventor
Hiroshi Handa
Hideki Ando
Takumi Itoh
Kentaro Hotta
Original Assignee
Tokyo Inst Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo Inst Tech filed Critical Tokyo Inst Tech
Publication of HK1173219A1 publication Critical patent/HK1173219A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HK13100395.6A 2009-10-20 2013-01-10 Screening method utilizing thalidomide-targeting factor HK1173219A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009241290 2009-10-20
PCT/JP2010/068272 WO2011049043A1 (ja) 2009-10-20 2010-10-18 サリドマイド標的因子を利用したスクリーニング方法

Publications (1)

Publication Number Publication Date
HK1173219A1 true HK1173219A1 (en) 2013-05-10

Family

ID=43900269

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13100395.6A HK1173219A1 (en) 2009-10-20 2013-01-10 Screening method utilizing thalidomide-targeting factor

Country Status (11)

Country Link
US (1) US9217743B2 (xx)
EP (1) EP2492686B1 (xx)
JP (1) JP5660578B2 (xx)
KR (1) KR101692297B1 (xx)
CN (1) CN102576023B (xx)
AU (1) AU2010309035B2 (xx)
CA (1) CA2774871C (xx)
HK (1) HK1173219A1 (xx)
HU (1) HUE039781T2 (xx)
RU (1) RU2528380C2 (xx)
WO (1) WO2011049043A1 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120134969A1 (en) 2009-05-25 2012-05-31 Hiroshi Handa Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
AU2012249491B2 (en) 2011-04-29 2016-12-15 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
WO2014004990A2 (en) * 2012-06-29 2014-01-03 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
WO2014028445A2 (en) * 2012-08-14 2014-02-20 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
EP2757379A1 (en) * 2013-01-16 2014-07-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method to screen for the teratogenic potential of substances
KR20140100731A (ko) * 2013-02-07 2014-08-18 광주과학기술원 Ｃｒｂ ｎ ｋｏ 마우스의 제조방법 및 이의 용도
US20160282354A1 (en) 2013-11-08 2016-09-29 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
WO2015085172A2 (en) * 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
US10092555B2 (en) 2014-06-27 2018-10-09 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
WO2017044793A1 (en) 2015-09-11 2017-03-16 The Brigham And Women's Hospital, Inc. Methods of characterizing resistance to modulators of cereblon
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
BR112020007576A2 (pt) 2017-10-18 2020-09-24 Novartis Ag composições e métodos para degradação de proteína seletiva
CA3081856C (en) * 2017-11-09 2022-07-26 Dana-Farber Cancer Institute, Inc. Methods to prevent teratogenicity of imid like molecules and imid based degraders/protacs
US11236103B2 (en) 2018-07-27 2022-02-01 Biotheryx, Inc. Bifunctional compounds
WO2020102195A1 (en) 2018-11-13 2020-05-22 Biotheryx, Inc. Substituted isoindolinones
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
CN111678756A (zh) * 2020-06-12 2020-09-18 苏州木芮生物科技有限公司 斑马鱼软骨染色一步法试剂盒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002257195A1 (en) * 2001-04-23 2002-11-05 University Of Virginia Patent Foundation Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
BRPI0416275A (pt) * 2003-11-06 2007-01-23 Celgene Corp métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
CN1696127A (zh) * 2005-04-18 2005-11-16 中国科学院长春应用化学研究所 沙利度胺的类似物及其制备方法
WO2007097109A1 (ja) * 2006-02-20 2007-08-30 National University Corporation Tokyo Medical And Dental University 抗関節リウマチ活性を有する物質のスクリーニング方法及び評価方法
CN101017166A (zh) * 2007-01-18 2007-08-15 复旦大学 人rtn4b蛋白在制备抗肿瘤药物中的应用
KR100901128B1 (ko) * 2007-07-10 2009-06-04 한국과학기술연구원 탈리도마이드 처리에 따른, 최기형성 유발 약물 검색용마커유전자 및 이를 이용한 검색 방법
KR100974228B1 (ko) * 2007-11-16 2010-08-06 한국과학기술연구원 최기형성 및 부작용 유발 약물 검색용 바이오마커 및 이를이용한 최기형성 및 부작용 유발 약물 검색 방법

Also Published As

Publication number Publication date
AU2010309035B2 (en) 2014-01-30
RU2528380C2 (ru) 2014-09-20
KR101692297B1 (ko) 2017-01-04
EP2492686A1 (en) 2012-08-29
CA2774871C (en) 2018-05-29
EP2492686A4 (en) 2013-07-17
JPWO2011049043A1 (ja) 2013-03-14
CA2774871A1 (en) 2011-04-28
CN102576023A (zh) 2012-07-11
US20120192297A1 (en) 2012-07-26
EP2492686B1 (en) 2018-06-13
US9217743B2 (en) 2015-12-22
JP5660578B2 (ja) 2015-01-28
CN102576023B (zh) 2014-07-09
WO2011049043A1 (ja) 2011-04-28
KR20120093852A (ko) 2012-08-23
HUE039781T2 (hu) 2019-02-28
RU2012120710A (ru) 2013-11-27
AU2010309035A1 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
HK1173219A1 (en) Screening method utilizing thalidomide-targeting factor
GB0905140D0 (en) Method
GB0911905D0 (en) Method
GB0902476D0 (en) Method
GB0910707D0 (en) Method
GB0913525D0 (en) Method
GB0913433D0 (en) Method
GB0901444D0 (en) Method
GB0905367D0 (en) Method
GB0903316D0 (en) Method
GB0917457D0 (en) Method
GB0908770D0 (en) Method
GB0916570D0 (en) Method
GB0916013D0 (en) Method
EP2646824A4 (en) SCREENING METHOD
GB0902034D0 (en) Method
GB0900560D0 (en) Method
EP2520659A4 (en) SCREENING PROCESS
EP2471918A4 (en) SCREENING PROCESS
GB0912394D0 (en) Screening methods
EP2243830A4 (en) SCREENING PROCESS
GB0904946D0 (en) Method
GB0914702D0 (en) Method
GB0911362D0 (en) Method
GB0908816D0 (en) Method

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211016